Assertio Inc. (ASRT)
0.81
0.01 (0.87%)
At close: Feb 20, 2025, 3:59 PM
0.80
-0.63%
After-hours: Feb 20, 2025, 06:27 PM EST
undefined% (undefined)
| Bid | 0.77 |
| Market Cap | 76.87M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.44 |
| PE Ratio (ttm) | -1.83 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.82 |
| Volume | 265,772 |
| Avg. Volume (20D) | 600,150 |
| Open | 0.81 |
| Previous Close | 0.80 |
| Day's Range | 0.80 - 0.82 |
| 52-Week Range | 0.73 - 1.80 |
| Beta | undefined |
About ASRT
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, ...
Sector Healthcare
IPO Date Dec 3, 1997
Employees 53
Stock Exchange NASDAQ
Ticker Symbol ASRT
Website https://www.assertiotx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 272.62% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Assertio Inc. is scheduled to release its earnings on Mar 10, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+8.82%
Assertio Holdings shares are trading higher. The c...
Unlock content with
Pro Subscription
3 months ago
-15.84%
Assertio Holdings shares are trading lower. Buxton Helmsley issued a letter to the companies shareholders disclosing its short position.
